Synthesis and biological evaluation of lipophilic Ca1a 2L analogues as potential bisubstrate inhibitors of protein:geranylgeranyl transferase-1

Bioorganic and Medicinal Chemistry

Volumn 13, Issue 5, 2005, Pages 1463-1475

  El Oualid, Farid ^a   Baktawar, Jayand ^a   Leroy, Ingrid M ^b   Van Den Elst, Hans ^a   Cohen, Louis H ^b   Van Der Marel, Gijs A ^a   Overkleeft, Herman S ^a   Overhand, Mark ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Oncogenic Ras; Peptidomimetics; Potential bisubstrate inhibitors; Protein:geranylgeranyl transferase 1

Indexed keywords

AMINO ACID; CALCIUM DERIVATIVE; GLUCOSE DERIVATIVE; LIPID; N [6 [[N [N (PALMITIC ACID)GLYCINE]] S TERT BUTYLTHIOCYSTEINYL]AMINOMETHYL 4,5 DIDEOXY ALPHA DEXTRO GLUCURONOPYRANOSYL]LEUCINE; N [6 [[N [N 4 (PALMITIC ACID)AMINOBUTYRIC ACID]]CYSTEINYL]AMINOMETHYL 4,5 DIDEOXY ALPHA DEXTRO GLUCURONOPYRANOSYL]LEUCINE; PROTEIN GERANYLGERANYL TRANSFERASE 1 INHIBITOR; PROTEIN INHIBITOR; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; IC 50; LIPOPHILICITY; SYNTHESIS;

ALKYL AND ARYL TRANSFERASES; DIPEPTIDES; ENZYME INHIBITORS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; SUBSTRATE SPECIFICITY;

EID: 13444252661     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.12.035     Document Type: Article

References (48)

1. R.J.A. Grand, and D. Owen Biochem. J. 279 1991 609
2. M. Barbacid Annu. Rev. Biochem. 56 1987 779
3. M.C. Seabra Cell Signal. 10 1998 167
4. D.R. Lowy, and B.M. Willumsen Annu. Rev. Biochem. 62 1993 851
5. S. Pells, M. Divjak, P. Romanowski, H. Impey, N.J. Hawkins, A.R. Clarke, M.L. Hooper, and D.J. Williamson Oncogene 15 1997 1781
6. A.M. Duursma, and R. Agami Sem. Cancer Biol. 13 2003 267
7. D.M. Leonard J. Med. Chem. 40 1997 2971
8. S.B. Long, P.J. Casey, and L.S. Beese Nature 419 2002 645
9. S.B. Long, P.J. Hancock, A.M. Kral, H.W. Hellinga, and L.S. Beese Proc. Natl. Acad. Sci. U.S.A. 98 2001 12948
10. C.L. Strickland, W.T. Windsor, R. Syto, L. Wang, R. Bond, Z. Wu, J. Schwartz, H.V. Le, L. Beese, and P.C. Weber Biochemistry 37 1998 16601
11. H.-W. Park, S.R. Boduluri, J.F. Moomaw, P.J. Casey, and L.S. Beese Science 275 1997 1800
12. See: J.S. Taylor, T.S. Reid, K.L. Terry, P.J. Casey, and L.S. Beese EMBO J. 22 2003 5963 and references cited herein
13. The third member of the family is protein:geranylgeranyl transferase-2 (PGGT-2), which until now is only known to prenylate Rab proteins. See: H. Zhang, M.C. Seabra, and J. Deisenhofer Structure 8 2000 241
14. H. Zhang Structure 11 2003 237
15. These proteins are involved in various key biological processes, such as cell proliferation, differentation, growth, regulation of the cytoskeleton and vesicular transport
16. T.S. Reid, K.L. Terry, P.J. Casey, and L.S. Beese J. Mol. Biol. 343 2004 417
17. P. Casey, J.A. Thissen, and J.F. Moomaw Proc. Natl. Acad. Sci. U.S.A. 88 1991 8631
18. K. Yokoyama, G.W. Goodwin, F. Ghomaschi, J.A. Glomset, and M.H. Gelb Proc. Natl. Acad. Sci. U.S.A. 88 1991 5302
19. At the moment four PFT inhibitors have been evaluated in clinical trials (I-III). See: J. Mazieres, A. Pradines, and G. Favre Cancer Lett. 206 2004 159
20. I.M. Bell J. Med. Chem. 47 2004 1869
21. Inhibitors have also been identified from natural sources: A. Pedretti, L. Villa, and G. Vistoli J. Med. Chem. 45 2002 1460 (and references cited herein)
22. and by screening of compound libraries J.D. Scholten, K. Zimmerman, M. Oxender, J. Sebolt-Leopold, R. Gowan, D. Leonard, and D.J. Hupe Bioorg. Med. Chem. 4 1996 1537
23. For examples of bisubstrate design in drug development, see: C. Lerner, B. Masjost, A. Ruf, V. Gramlich, R. Jakob-Roetne, G. Zürchner, E. Borroni, and F. Diederich Org. Biomol. Chem. 1 2003 42
24. W.T. Miller Nat. Struct. Biol. 8 2001 16
25. K. Parang, J.H. Till, A.J. Ablooglu, R.A. Kohanski, S.R. Hubbard, and P.A. Cole Nat. Struct. Biol. 8 2001 37
26. E. Wolf, J. De Angelis, E.M. Khalil, P.A. Cole, and S.K. Burley J. Mol. Biol. 317 2002 215
27. K.L. Levert, and G.L. Waldrop Biochem. Biophys. Res. Commun. 291 2002 1213
28. I. Sattler, M. Böhm, and M. Schlitzer Bioorg. Med. Chem. 10 2002 615
29. A. Mitsch, S. Bergemann, R. Gust, I. Sattler, and M. Schlitzer Arch. Pharm. Med. Chem. 396 2003 242
30. M. Schlitzer, M. Böhm, I. Sattler, and H.-M. Dahse Bioorg. Med. Chem. 8 2000 1991
31. M. Schlitzer, and I. Sattler Angew. Chem., Int. Ed. 38 1999 2032
32. M. Schlitzer, I. Sattler, and H.-M. Dahse Bioorg. Med. Chem. 7 1999 2037
33. M. Schlitzer, and I. Sattler Eur. J. Med. Chem. 35 2000 721
34. M. Schlitzer, M. Böhm, and I. Sattler Bioorg. Med. Chem. 6 2000 2399
35. M. Thutewohl, L. Kissau, B. Popkirova, I.-M. Karaguni, T. Nowak, M. Bate, J. Kuhlmann, O. Müller, and H. Waldmann Bioorg. Med. Chem. 6 2003 2617
36. D.V. Patel, E.M. Gordon, R.J. Schmidt, H.N. Weller, M.G. Young, R. Zahler, M. Barbacid, J.M. Carboni, J.L. Gullo-Brown, L. Hunihan, C. Ricca, S. Robinson, B.R. Seizinger, V.A. Tuomari, N. Yan, and V. Manne J. Med. Chem. 38 1995 435
37. D.V. Patel, M.G. Young, S.P. Robinson, L. Hunihan, B.J. Dean, and E.M. Gordon J. Med. Chem. 39 1996 4197
38. R.S. Bhide, D.V. Patel, M.M. Patel, S.P. Robinson, L.W. Hunihan, and E.M. Gordon Bioorg. Med. Chem. Lett. 4 1994 2107
39. V. Manne, J. Yan, J.M. Carboni, A.V. Tuomari, C.S. Ricca, J.L. Gullo-Brown, M.L. Andahazy, R.J. Schmidt, D.V. Patel, R. Zahler, C.J. Der, A.D. Cox, R. Weinmann, J.T. Hunt, M. Barbacid, and B.R. Seizinger Oncogene 10 1995 1763
40. H.S. Overkleeft, S.H.L. Verhelst, E. Pieterman, N. Meeuwenoord, M. Overhand, L.H. Cohen, G.A. van der Marel, and J.H. van Boom Tetrahedron Lett. 40 1999 4103
41. M. Overhand, E. Pieterman, L.H. Cohen, A.R.P.M. Valentijn, G.A. van der Marel, and J.H. van Boom Bioorg. Med. Chem. Lett. 7 1997 2435
42. M. Overhand, H.R. Stuivenberg, E. Pieterman, L.H. Cohen, R.E.W. van Leeuwen, A.R.P.M. Valentijn, H.S. Overkleeft, G.A. van der Marel, and J.H. van Boom Bioorg. Chem. 26 1998 269
43. L.H. Cohen, E. Pieterman, R.E.W. van Leeuwen, P. Nègre-Aminou, A.R.P.M. Valentijn, M. Overhand, G.A. van der Marel, and J.H. van Boom Biochem. Pharm. 57 1999 365
44. L.H. Cohen, A.R.P.M. Valentijn, L. Roodenburg, R.E.W. van Leeuwen, R.H. Huisman, R.J. Lutz, G.A. van der Marel, and J.H. van Boom Biochem. Pharm. 49 1995 839
45. L.H. Cohen, E. Pieterman, R.E.W. van Leeuwen, B.E.A. Burm, G.A. van der Marel, and J.H. van Boom Biochem. Pharm. 60 2000 1061
46. F. El Oualid, B.E.A. Burm, I.M. Leroy, L.H. Cohen, J.H. van Boom, H. van den Elst, H.S. Overkleeft, G.A. van der Marel, and M. Overhand J. Med. Chem. 47 2004 3920
47. F. El Oualid, L. Bruining, I.M. Leroy, L.H. Cohen, J.H. van Boom, G.A. van der Marel, H.S. Overkleeft, and M. Overhand Helv. Chim. Acta 85 2002 3455
48. Chaetomellic acid consists of a fatty alkyl chain and is a natural PFT inhibitor. See: J.B. Gibbs, D.L. Pompliano, S.D. Mosser, E. Rands, R.B. Lingham, S.B. Singh, E.M. Scolnick, N.E. Kohl, and A. Oliff J. Biol. Chem. 268 1993 7617